argus

Lincoln Pharmaceuticals ltd.

NSE: LINCOLNINE405C010351,223 Cr

Timeline

Time (IST)TypeMEventSrc
29 Aug, 03:22 pmLincoln Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 11-Sep-2026.nse
29 Aug, 03:15 pmLincoln Pharmaceuticals Ltd - 531633 - Intimation Of Book Closure And Record Date For The Purpose Of 32Nd Annual General Meeting And Final Dividend For The Financial Year 2025-26.bse
29 Aug, 03:05 pmLincoln Pharmaceuticals Ltd - 531633 - Corporate Action-Fixes Book Closure For Determining The Dividend, If Approved At The AGMbse
13 Aug, 11:49 amLincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.nse
13 Aug, 11:46 amLincoln Pharmaceuticals Ltd - 531633 - Un-Audited Financial Results For Quarter Ended On 30 June, 2026.bse
13 Aug, 11:37 amLincoln Pharmaceuticals Ltd - 531633 - Board Meeting Outcome for Board Meeting Outcome For Un-Audited Financial Results For The Quarter Ended On June 30, 2026.bse
06 Aug, 12:37 pmLincoln Pharmaceuticals Ltd - 531633 - Board Meeting Intimation for Board Meeting Intimation For Consideration And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.bse
29 May, 03:08 pmLincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication with respect to Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Year ended March 31, 2026.nse
28 May, 05:24 pmLincoln Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 28, 2026, recommended Final Dividend of Rs. 1.80 per equity share.nse
28 May, 05:21 pmLincoln Pharmaceuticals Ltd - 531633 - Corporate Action-Board approves Dividendbse
28 May, 05:16 pmLincoln Pharmaceuticals Ltd - 531633 - Audited Financial Results For The Quarter And Year Ended 31St March, 2026bse
28 May, 05:09 pmLincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.nse
28 May, 05:09 pmLincoln Pharmaceuticals Ltd - 531633 - Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Quarter And Year Ended 31St March, 2026.bse
18 May, 02:42 pmLincoln Pharmaceuticals Ltd - 531633 - Corporate Action-Board to consider Dividendbse
18 May, 02:36 pmLincoln Pharmaceuticals Ltd - 531633 - Board Meeting Intimation for Consideration Of Audited (Standalone & Consolidated) Financial Results Of The Company For The Quarter And Year Ended On March 31, 2026.bse
12 May, 07:28 pmLincoln Pharmaceuticals Ltd - 531633 - Compliances-Reg.24(A)-Annual Secretarial Compliancebse
05 May, 04:52 pmLincoln Pharmaceuticals Ltd - 531633 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2bse
16 Apr, 02:25 pmLincoln Pharmaceuticals Ltd - 531633 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure Abse
08 Apr, 06:25 pmThe Exchange had sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI. The response of the Company is enclosed.nse
08 Apr, 04:01 pmMunjal Mahendrabhai Patel has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.nse
08 Apr, 04:00 pmMunjal Mahendrabhai Patel has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.nse
23 Feb, 11:36 amLincoln Pharmaceuticals Limited has informed the Exchange about Transcript of the investor meet held on February 18, 2026.nse
23 Feb, 11:33 amLincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
18 Feb, 06:36 pmLincoln Pharmaceuticals Limited has informed the Exchange about Link of Recording for the Investor call held today.nse
18 Feb, 06:32 pmLincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
13 Feb, 05:46 pmLincoln Pharmaceuticals Limited has informed the Exchange about Schedule of Earnings Conference Call to discuss the unaudited financial results of the Company for the Quarter and Nine months ended December-2025.nse
12 Feb, 11:38 amLincoln Pharmaceuticals Ltd - 531633 - UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2025bse
12 Feb, 11:30 amLincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.nse
12 Feb, 11:29 amLincoln Pharmaceuticals Ltd - 531633 - Board Meeting Outcome for OUTCOME OF BOARD MEETINGbse
04 Feb, 12:07 pmLincoln Pharmaceuticals Ltd - 531633 - Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Third Quarter And Nine Months Ended 31St December, 2025.bse
10 Jan, 04:52 pmLincoln Pharmaceuticals Limited has informed the Exchange about Credit Ratingnse
10 Jan, 04:46 pmLincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Credit Ratingbse
07 Jan, 05:52 pmThe Exchange has sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.nse
14 Nov, 02:43 pmLincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication with respect to unaudited financial results of the company for the quarter and half year ended on 30.09.2025.nse
13 Nov, 12:33 pmLincoln Pharmaceuticals Ltd - 531633 - UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2025bse
13 Nov, 12:32 pmLincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.nse
13 Nov, 12:28 pmLincoln Pharmaceuticals Ltd - 531633 - Board Meeting Outcome for UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2025bse
05 Nov, 03:04 pmLincoln Pharmaceuticals Ltd - 531633 - Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter And Half Year Ended 30.09.2025.bse
06 Sept, 04:21 pmLincoln Pharmaceuticals Limited has informed the Exchange about Intimation regarding dispatch of physical communication to the Shareholders who have not registered their email address.nse
06 Sept, 04:16 pmLincoln Pharmaceuticals Ltd - 531633 - General Updatesbse
06 Sept, 03:13 pmLincoln Pharmaceuticals Ltd - 531633 - Reg. 34 (1) Annual Report.bse